Neurology and Therapy最新文献

{"title":"The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity.","authors":"James E Galvin, Michael J Kleiman, Heather M Harris, Paul W Estes","doi":"10.1007/s40120-025-00741-x","DOIUrl":"https://doi.org/10.1007/s40120-025-00741-x","url":null,"abstract":"<p><strong>Introduction: </strong>At the present time, clinical detection of individuals who have amyloid in their brain is not possible without expensive biomarkers. The objective of the study was to test whether Cognivue Clarity^® can differentiate True Controls, preclinical Alzheimer's disease (pAD), mild cognitive impairment (MCI) due to Alzheimer's disease (MCI-AD), AD, and MCI and dementia due to non-AD etiologies enrolled in the Bio-Hermes Study.</p><p><strong>Methods: </strong>A total of 887 individuals completed Cognivue Clarity, amyloid PET scan, and blood-based AD biomarkers. Three Cognivue Clarity subtests differentiated between True Controls and pAD, and between cognitive impairment due to AD versus non-AD processes. This finding was leveraged to develop an amyloid-specific marker, combining the three subtests with age using machine learning to create the 4-point Cognivue Amyloid Risk Measure (CARM).</p><p><strong>Results: </strong>Cognivue Clarity discriminated cognitively normal from cognitively impaired individuals (p < 0.001, Cohen's d = 0.732). The CARM differentiated between individuals with amyloid and without amyloid by PET (p < 0.001, Cohen's d = 0.618) and blood-based biomarkers (p's < 0.001). Amyloid positivity and cognitive impairment increased across four CARM thresholds (p < 0.001). Dichotomizing CARM thresholds into low (CARM1/CARM2) and high (CARM3/CARM4) likelihood provided excellent discrimination for amyloid PET positivity (OR: 3.67; 95% CI 2.76-4.89). CARM categories differentiated between True Controls, pAD, MCI-AD, AD, and cognitive impairment due to non-AD etiologies (χ² = 137.6, p < 0.001) with the majority of True Controls and non-AD etiologies being in CARM1/CARM2, and the majority of pAD, MCI-AD, and AD being in CARM3/CARM4.</p><p><strong>Conclusions: </strong>Cognivue Clarity detects individuals with cognitive impairment, and a derivation benchmarked against amyloid PET was used to develop the CARM to predict the presence of amyloid. Combining the CARM and the Cognivue Clarity overall score could help identify individuals with and without cognitive impairment due to AD or non-AD etiologies, help screen for treatment protocols with anti-amyloid therapies, enrich clinical trial recruitment, and help to identify pAD for prevention studies.</p><p><strong>Trial registration: </strong>ClinicalTrials. gov identifier, NCT04733989.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis.","authors":"Michael Levraut, Cassandre Landes-Chateau, Lydiane Mondot, Mikael Cohen, Christine Lebrun-Frenay","doi":"10.1007/s40120-025-00737-7","DOIUrl":"https://doi.org/10.1007/s40120-025-00737-7","url":null,"abstract":"<p><p>At the last European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Montalban and the experts' panel announced the 2024 revision of the McDonald criteria. The optic nerve has been added as a fifth dissemination in space (DIS) criteria topography among the main changes. Multiple sclerosis (MS) can be diagnosed in patients with radiologically isolated syndrome (RIS) if specific biomarkers are added to at least two of the five DIS criteria. Among the particular MS biomarkers, the kappa free light chain index (kFLC index) positivity will be added to oligoclonal band (OCB) detection to fulfill intrathecal immunoglobulin synthesis, and the central vein sign (CVS) will be able to ensure the specificity of the lesions detected on MRI scans. This review summarises the knowledge on the kFLC index and the CVS in people with MS and RIS, allowing them to be incorporated into the proposed revision of the McDonald criteria.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.","authors":"Erin Furr Stimming, Daniel O Claassen, Ginny P Sen, Olga Klepitskaya, Michael Serbin, Hyunwoo Kim, Sean C Hinton, Dietrich Haubenberger","doi":"10.1007/s40120-025-00731-z","DOIUrl":"https://doi.org/10.1007/s40120-025-00731-z","url":null,"abstract":"","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.","authors":"Juliana West, Maggie Li, Sabrina Wong, Gia Han Le, Kayla M Teopiz, Kyle Valentino, Christine E Dri, Roger S McIntyre","doi":"10.1007/s40120-025-00724-y","DOIUrl":"https://doi.org/10.1007/s40120-025-00724-y","url":null,"abstract":"<p><strong>Introduction: </strong>Glucagon-like peptide-1 (GLP-1) is an incretin hormone that modulates glucose metabolism and insulin secretion. Recent translational and clinical research has evaluated the effects of GLP-1 receptor agonists (GLP-1 RAs), a class of drugs that mimic the action of native GLP-1 in the central nervous system (CNS). In addition to the efficacy of GLP-1 for the treatment of diabetes mellitus and obesity, preliminary evidence indicates GLP-1s have neuroprotective, therapeutic, and disease modification effects for select neurodegenerative disorders (e.g. Parkinson's disease, Alzheimer's disease). Among the available GLP-1 RAs, relatively few have been shown to be CNS penetrant. This article synthesizes extant literature reporting on CNS penetrants of GLP-1 RAs as proxied by brain imaging studies. Where available, studies that reported on the bioavailability of GLP-1 RAs in the CNS were identified.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Ovid, and Web of Science from database inception to July 2024 was conducted. Inclusion criteria were English language publications with no date restrictions, preclinical and clinical studies with participants aged 18-80 and studies which focused on GLP-1 RAs including: \"Semaglutide\" or \"Ozempic\" or \"Rybelsus\" or \"Wegovy\" or \"Dulaglutide\" or \"Trulicity\" or \"Exenatide\" or \"Byetta\" or \"Bydureon\" or \"Liraglutide\" or \"Lixisenatide\" or \"Tirzepatide\" or \"Mounjaro\" or \"Zepbound\" or \"Bydureon BCise\" or \"Adlyxin\" or \"Victoza\" or \"Saxenda\".</p><p><strong>Results: </strong>We identified 14 studies that were included in this synthesis. Preclinical studies suggest that select GLP-1 RAs cross the blood-brain barrier (BBB) (i.e. liraglutide, semaglutide, and exenatide). Replicated evidence suggests that CNS penetration of GLP-1 RAs can be proxied by reported effects of GLP-1 RAs on brain connectivity in human participants.</p><p><strong>Conclusion: </strong> Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Podcast on the Rhythms of Healing: Patient and Physician Insights on Art, Music, Dance Therapy and Creativity in Parkinson's Disease.","authors":"Caroline Cowan, Richard Walker","doi":"10.1007/s40120-024-00688-5","DOIUrl":"10.1007/s40120-024-00688-5","url":null,"abstract":"<p><p>This is an outline for a podcast. Parkinson's Disease (PD) is a progressive neurodegenerative disease in which there is increasing loss of dopamine neurones from the basal ganglia (Simon et al. Clin Geriatr Med. 36(1):1-12). Motor symptoms, which are usually asymmetrical, include resting tremor, rigidity, bradykinesia (slow movement) and, usually later on, postural instability. PD is primarily a clinical diagnosis although a DaTscan, which if positive shows asymmetrical loss of dopamine uptake in the basal ganglia, is helpful in cases of doubt (Tsang and Walker J Neurol 270(5):2550-2558).</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"429-436"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review.","authors":"Vicente Villanueva, Victor Soto-Insuga, Patricia Smeyers, Ángel Aledo-Serrano, Rocío Sánchez-Carpintero, Juan García-Peñas, Antonio Gil-Nagel","doi":"10.1007/s40120-025-00713-1","DOIUrl":"10.1007/s40120-025-00713-1","url":null,"abstract":"<p><strong>Introduction: </strong>Fenfluramine (FFA) represents the latest therapeutic option approved for seizure management in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) for patients aged ≥ 2 years. This article provides expert guidance for optimizing FFA therapy to support clinical decision-making in these populations.</p><p><strong>Methods: </strong>A panel of Spanish experts specialized in developmental epileptic encephalopathies (DEEs) has developed practical recommendations for the clinical use of FFA, focusing on key aspects of FFA management: mechanism of action, pharmacokinetics including drug interactions, titration, efficacy, safety and tolerability, contraindications, and considerations for its broader application in DEEs. The methodology adopted in this project was an expert-opinion, evidence-based approach.</p><p><strong>Results: </strong>The panel issued targeted recommendations, including a modified titration strategy slower than the product guidelines, adjusted for possible antiseizure concomitant medications, and management of other concomitant treatments. Key efficacy indicators, such as reductions in seizure frequency and severity of the most disabling seizures, were emphasized as core measures for treatment evaluation. Periodic assessments of non-seizure outcomes and daily life activities are recommended during follow-up to comprehensively capture treatment outcomes. The panel noted that their clinical observations align with positive findings from clinical trials, suggesting a potential role for FFA in other DEEs, tailored to individual electroclinical and etiological profiles.</p><p><strong>Conclusion: </strong>This article presents expert practical recommendations for the management and treatment optimization of FFA in patients with DEEs, supporting clinicians in achieving improved patient outcomes.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"447-465"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Surgical Therapies for Drug-Resistant Epilepsy: A Paradigm Shift towards Precision Care.","authors":"Chen Zhong, Kang Yang, Nianhua Wang, Liang Yang, Zhuanyi Yang, Lixin Xu, Jun Wang, Longbo Zhang","doi":"10.1007/s40120-025-00710-4","DOIUrl":"10.1007/s40120-025-00710-4","url":null,"abstract":"<p><p>Epilepsy, a prevalent neurological disorder characterized by recurrent seizures, affects millions worldwide, with a significant proportion resistant to pharmacological treatments. Surgical interventions have emerged as pivotal in managing drug-resistant epilepsy (DRE), aiming to reduce seizure frequency or achieve seizure freedom. Traditional resective surgeries have evolved with technological advances, enhancing precision and safety. Neurostimulation techniques, such as responsive neurostimulation (RNS) and deep brain stimulation (DBS), now provide personalized, real-time seizure management, offering alternatives to traditional surgery. Minimally invasive ablative methods, such as laser interstitial thermal therapy (LITT) and Magnetic Resonance-guided Focused Ultrasound (MRgFUS), allow for targeted destruction of epileptogenic tissue with reduced risks and faster recovery times. The use of stereo-electroencephalography (SEEG) and robotic assistance has further refined surgical precision, enhancing outcomes. These advancements mark a paradigm shift towards precision medicine in epilepsy care, promising improved seizure management and quality of life for patients globally. This review outlines the latest innovations in epilepsy surgery, emphasizing their mechanisms and clinical implications to improve outcomes for patients with DRE.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"467-490"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine.","authors":"Paola Zaratin, Per Soelberg Sørensen, Óscar Fernández, Giancarlo Comi","doi":"10.1007/s40120-024-00706-6","DOIUrl":"10.1007/s40120-024-00706-6","url":null,"abstract":"<p><p>Using the case study of the Multiple Sclerosis Care Unit Initiative launched by the European Charcot Foundation, we discuss the need to evaluate the impact of multidisciplinary and multi-stakeholder healthcare systems on patient-reported experience and outcomes for the programming and monitoring of brain and neurodegenerative diseases in Europe and beyond. The multiple sclerosis (MS) case study presented in this paper highlights the role of patient-generated data as indicators of the impact of value-based healthcare (VBHC) for all the different neurological diseases whose prodromal symptoms are the first signs of disease progression and therefore instrumental markers for preventive treatments to preserve brain health. A holistic approach to the treatment of MS plays a crucial role in the inclusion and scientific meaning of the patient's perspective in terms of patient-reported dimension and patient-generated health data (PGHD).</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"437-446"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Objective Tool to Assess Tremor Reveals Unilateral Focused Ultrasound Improves Tremor Bilaterally.","authors":"Vered Aharonson, Teddy Lazebnik, Alon Sinai, Maria Nassar, Inna Senderova, Marius Constantinescu, Lior Lev Tov, Ilana Schlesinger","doi":"10.1007/s40120-024-00705-7","DOIUrl":"10.1007/s40120-024-00705-7","url":null,"abstract":"<p><strong>Background: </strong>Tremor in essential tremor and in tremor-dominant Parkinson's disease is assessed by subjective observations in patients undergoing focused ultrasound thalamotomy, a minimally invasive procedure intended to alleviate tremor in these patients.</p><p><strong>Objective: </strong>To develop an objective tool for tremor analysis to be used before and after focused ultrasound thalamotomy treatment in the treated hand (contralateral to ablation) and non-treated (ipsilateral to ablation).</p><p><strong>Methods: </strong>Using image processing and signal processing that utilized images of a Archimedes spiral drawing, we created a tool to analyze tremor. First, we showed that the proposed tool reproduces known clinical dynamics on the treated hand, and then we used it to evaluate the clinical dynamics on the non-treated hand.</p><p><strong>Results: </strong>Using the tool we developed, we were able to demonstrate a significant reduction in tremor following focused ultrasound thalamotomy among 132 essential tremor and 26 tremor-dominant Parkinson's disease patients in the treated hand using drawings of Archimedes spirals up to 1 year following the procedure. Thus, we reproduced known clinical data and therefore validated the proposed tool. In addition, we were able to demonstrate a significant improvement in the non-treated hand as well as a significant deterioration in the efficacy of focused ultrasound thalamotomy over time.</p><p><strong>Conclusion: </strong>Our objective method, which incorporated image processing and signal processing, provided a quantitative measure of tremor reduction following focused ultrasound thalamotomy. It demonstrated significant improvement in tremors in the treated and non-treated hands following focused ultrasound thalamotomy as well as deterioration in the efficacy of treatment over time. If replicated in other studies, this method may complement current subjective assessments.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"565-574"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.","authors":"Michele H Potashman, Evan Popoff, Lauren C Powell, Melissa Wolfe Beiner, Ainsley Mackenzie, Vlad Coric, Sub Subramony, Matthis Synofzik, Jeremy Schmahmann, Gilbert L'Italien","doi":"10.1007/s40120-024-00708-4","DOIUrl":"10.1007/s40120-024-00708-4","url":null,"abstract":"<p><strong>Introduction: </strong>The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a valid, highly utilized measure for assessing ADL impacts in patients with Friedreich ataxia. We provide evidence of the psychometric validity of the FARS-ADL in two cohorts of patients with spinocerebellar ataxia (SCA).</p><p><strong>Methods: </strong>Using data from a cohort of real-world subjects with SCA (recruited at Massachusetts General Hospital [MGH]; n = 33) and a phase 3 trial of troriluzole in adults with SCA (NCT03701399 [Study 206]; n = 217), comprising a subset of patients with the SCA3 genotype (n = 89), the psychometric measurement properties and minimal change thresholds of the FARS-ADL were examined.</p><p><strong>Results: </strong>Ceiling effects for the FARS-ADL were absent within the MGH cohort while floor effects were observed for eight of nine items. Excellent internal consistency reliability was observed (α_total = 0.88; α_{items-removed} = 0.86-0.87), and item-to-total correlations were acceptable (r = 0.55-0.89 per item). Convergent and divergent validity were supported with strong correlations demonstrated between FARS-ADL and scales measuring similar concepts (Neuro-QOL [Upper], Neuro-QOL [Lower], PROM-ADL, PROM-PHYS, and FARS-FUNC; all P < 0.001) and weaker correlations shown between measures of differing constructs. A two- to three-point threshold for meaningful changes was supported as 0.5 × SD = 2.43, SEM = 2.19. Mean changes from baseline for subjects classified as \"improved,\" \"no change,\" or \"deteriorated\" were -0.54, 0.22, and 1.47, respectively. Similar trends were observed in the Study 206 all-SCA and SCA3 cohorts.</p><p><strong>Conclusion: </strong>Psychometric evaluation showed that the FARS-ADL performed well on analyses examining the reliability and validity of the measure and can detect meaningful changes in patients with SCA, including those with SCA3.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT03701399 (Study 206).</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"527-545"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}